<DOC>
	<DOCNO>NCT00343668</DOCNO>
	<brief_summary>The primary goal phase II trial evaluate response rate combination chemotherapy S-1 Irinotecan patient advance gastric cancer first-line therapy .</brief_summary>
	<brief_title>S-1 Irinotecan Combination Chemotherapy Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Pathologically proven unresectable adenocarcinoma stomach With unidimensionally measurable disease ( least long diameter 2 cm conventional CT scan , xray physical examination , 1cm spiral CT scan ) Age 18 70 year old Estimated life expectancy 3 month ECOG performance status 2 low Adequate bone marrow function ( absolute neutrophil count [ ANC ] ≥1,500/µL , hemoglobin ≥9.0 g/dL , platelet ≥100,000/µL ) Adequate kidney function ( serum creatinine &lt; 1.5 mg/dL ) Adequate liver function ( serum total bilirubin &lt; 2 time upper normal limit ( UNL ) ; serum transaminase level &lt; 3 time [ &lt; 5 time patient liver metastasis ] UNL ) No prior chemotherapy prior adjuvant chemotherapy finish least 6 month enrollment allow . ( , prior adjuvant chemotherapy capecitabine S1 camptothecin analogue exclude ) No prior radiation therapy least 4 week enrollment study Other tumor type adenocarcinoma Central nervous system ( CNS ) metastases prior radiation CNS metastases Gastric outlet obstruction intestinal obstruction Evidence gastrointestinal bleed The patient bony lesion sole evaluable disease . Past concurrent history neoplasm stomach cancer , except curatively treat nonmelanoma skin cancer situ carcinoma cervix uteri Pregnant lactate woman , woman childbearing potential employ adequate contraception Other serious illness medical condition Unstable cardiac disease despite treatment , myocardial infarction within 6 month prior study entry History significant neurologic psychiatric disorder include dementia seizure Active uncontrolled infection Other serious underlie medical condition could impair ability patient participate study Concomitant administration experimental drug investigation , concomitant chemotherapy , hormonal therapy , immunotherapy concomitant drug medication ; The follow drug cause drug interaction S1 . i. Warfarin , phenprocoumon : increase bleeding tendency ii . Increase blood concentration phenytoin iii . sorivudine : inhibit DPD &gt; increase toxicity accord fluoropyrimidine iv . allopurinol : decrease activity S1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>advanced gastric cancer</keyword>
	<keyword>First-line therapy</keyword>
	<keyword>S-1</keyword>
	<keyword>irinotecan</keyword>
</DOC>